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Background:  Subclassification of ovarian carcinomas can be used to guide treatment and
determine prognosis. Germline and somatic mutations, loss of heterozygosity (LOH), and
epigenetic events such as promoter hypermethylation can lead to decreased expression of BRCA1/
2 in ovarian cancers. The mechanism of BRCA1/2 loss is a potential method of subclassifying high
grade serous carcinomas.
Methods: A consecutive series of 49 ovarian cancers was assessed for mutations status of BRCA1
and BRCA2, LOH at the BRCA1 and BRCA2 loci, methylation of the BRCA1 promoter, BRCA1,
BRCA2, PTEN, and PIK3CA transcript levels, PIK3CA gene copy number, and BRCA1, p21, p53,
and WT-1 immunohistochemistry.
Results: Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or
epigenetic loss of BRCA1. All of these tumours were high-grade serous or undifferentiated type.
None of the endometrioid (n = 5), clear cell (n = 4), or low grade serous (n = 2) carcinomas
showed loss of BRCA1, whereas 47% of the 38 high-grade serous or undifferentiated carcinomas
had loss of BRCA1. It was possible to distinguish high grade serous carcinomas with BRCA1
mutations from those with epigenetic BRCA1 loss: tumours with BRCA1 mutations typically had
decreased PTEN mRNA levels while those with epigenetic loss of BRCA1 had copy number gain
of PIK3CA. Overexpression of p53 with loss of p21 expression occurred significantly more
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frequently in high grade serous carcinomas with epigenetic loss of BRCA1, compared to high grade
serous tumors without loss of BRCA1.
Conclusion: High grade serous carcinomas can be subclassified into three groups: BRCA1 loss
(genetic), BRCA1 loss (epigenetic), and no BRCA1 loss. Tumors in these groups show distinct
molecular alterations involving the PI3K/AKT and p53 pathways.
Background
Ovarian cancer is the most fatal gynecological cancer in
North American women and the fifth most common
cause of cancer death. Epithelial ovarian carcinomas
(EOC) are subclassified according to tumor cell type and
grade. These different subtypes of ovarian cancer are asso-
ciated with different molecular characteristics: high grade
serous cancers typically contain TP53 mutations [1,2], low
grade serous carcinomas often have RAS-RAF pathway
activation and mutations in the KRAS and BRAF genes [3],
low-grade endometrioid cancers are associated with muta-
tions in the beta-catenin gene, CTNNB1 [4], and muci-
nous cancers frequently have mutations in KRAS [5].
Accurate subclassification of ovarian cancers is essential
because different subtypes of ovarian cancer respond dif-
ferently to treatment and have different prognoses [6].
The majority of ovarian cancers are of serous subtype [7].
In a study of 220 ovarian carcinomas, over half were cate-
gorized as serous and over 90% of these serous ovarian
cancers were high grade (grade II or III) [8]. High grade
serous ovarian cancers are associated with BRCA1 or
BRCA2 mutations [9-11]. BRCA1, located at 17q21 [12-
14], and BRCA2, located at 13q12-q13 [15,16] both
encode tumor suppressors involved in repairing double-
stranded DNA breaks and maintaining genomic stability
[17-19] Germline BRCA1 or BRCA2 mutations are present
in 10% to 15% of all EOCs [20,21]. Less commonly,
EOCs contain somatic mutations in these genes [22]. In
addition, aberrant expression of BRCA1 or BRCA2 may
occur through loss of heterozygosity or, in the case of
BRCA1, promoter hypermethylation [23-27]. Unlike
breast cancer, where patients with germline mutations in
BRCA1 or BRCA2 have cancers that are distinct from spo-
radic breast cancers on the basis of morphology or gene
profiling [28-30], ovarian cancers with germline BRCA1
or BRCA2 mutations are indistinguishable from their spo-
radic counterparts [11,23,31-33]. High grade serous ovar-
ian cancers that have functional BRCA1 or BRCA2 are
currently not separable from high grade serous cancers
that have loss of function of these proteins, based on rou-
tine histopathological examination. The challenge is to
find methods to distinguish these subtypes of high grade
serous cancers; this would stratify patients based on the
underlying molecular events during oncogenesis, which is
potentially highly relevant as these cancers may respond
differently to treatment. This has recently been demon-
strated in vitro: inhibitors of poly(ADP-ribose) polymer-
ase (PARP1) were found to be able to target and kill cells
deficient in either BRCA1 or BRCA2 [34,35]. PARP1 binds
to single-stranded DNA breaks, attracting proteins to
repair DNA. Inhibition of PARP1 allows these single
stranded breaks to progress to double stranded breaks
through the resulting collapse of replication forks [34,36].
The preferred double-strand break repair mechanism is
homologous recombination which relies on the activity of
BRCA1 and BRCA2. Thus, cells with loss of BRCA1 or
BRCA2 function that are treated with PARP1 inhibitors are
unable to repair DNA breaks, which leads to crisis and cell
death.
We collected and analysed 49 consecutive ovarian tumor
samples from consenting women diagnosed with inva-
sive, non-mucinous EOC who were undergoing debulk-
ing surgery. We pathologically characterized these
samples and analysed them for BRCA1 and BRCA2 muta-
tions, loss of heterozygosity at both loci, mRNA levels of
BRCA1 and BRCA2, expression of BRCA1, and BRCA1
promoter hypermethylation. In light of previous studies
showing that promoter hypermethylation of BRCA2 is
rarely if ever encountered in ovarian carcinoma [37-39],
we did not undertake similar studies on the BRCA2 pro-
moter. We then attempted to determine whether molecu-
lar profiles could be used to distinguish high grade serous
cancers with BRCA1 mutations (germline or somatic),
from high grade serous cancers with epigenetic loss of
BRCA1 through promoter hypermethylation, and high
grade serous cancers without BRCA1 loss. We focused on
the PI3K/AKT and p53 pathways which play important
roles in ovarian cancer [40-43].
Methods
Recruitment and tumor samples
Between January 2004 and September 2005 all women
undergoing primary debulking surgery for ovarian carci-
noma were invited to participate in this study at the Van-
couver General Hospital and British Columbia Cancer
Agency in Vancouver, Canada. Women with mucinous
and borderline tumors, and women who had received
pre-operative chemotherapy were excluded. Pathology
was reviewed by a single pathologist (CBG). Serous
tumors were classified as low or high-grade as described
previously [44]; all undifferentiated and clear cell carcino-
mas were considered high-grade. Endometrioid carcino-BMC Cancer 2008, 8:17 http://www.biomedcentral.com/1471-2407/8/17
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mas were graded as grade 1, 2, or 3 according to the
Silverberg grading system [45]. Ethical approval was
obtained from the University of British Columbia Ethics
Board (#H02-61375 and #H03-70606).
DNA and RNA extraction
Cancer tissue was split with part stored at -80 degrees and
the facing tissue fixed in formalin and placed in paraffin
blocks. H&E sections were reviewed to ensure samples
consisted of ≥ 70% tumor cells. DNA was extracted using
the Puregene DNA Purification Kit (Gentra Systems, Inc,
Wicklow, Ireland) according to manufacturer's instruc-
tions from whole blood (germline analysis) or tumor
samples (somatic analysis). RNA was isolated with Trizol
(Invitrogen, Carlsbad, CA) according to standard proto-
cols.
Loss of heterozygosity analysis
Somatic loss of BRCA1/BRCA2 in tumor tissue was
assessed for LOH using microsatellite markers for BRCA1
(D17S855 (60°C), D17S1185 (58°C), D17S1323
(56°C), and D17S1325 (56°C)) [46], and BRCA2
(D13S260 (60°C), D13S171 (50°C), D13S267 (53°C),
D13S217 (55°C)) [9]. PCR products were electro-
phoresed in an ABI Prism 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA), and analyzed with Genescan
v3.1 software (Applied Biosystems, Foster City, CA). LOH
was defined as a complete or partial (≤ 50%) signal reduc-
tion of one allele in at least one marker. Microsatellite
instability (MSI) was defined as the presence of novel alle-
les in the tumor DNA that were not present in normal
DNA in at least one marker [47].
dHPLC mutation screening and mutation analysis
Screening for BRCA1/BRCA2 mutations was performed
using denaturing high performance liquid chromatogra-
phy (dHPLC). Tumor DNA was mixed in a 3:1 ratio with
corresponding germline DNA for all tumors shown to
possess LOH to ensure that LOH did not mask somatic
mutations [48]. For example, with intratumoral LOH, and
mutation of the remaining allele, dHPLC screening would
give a false negative result. If the mutation is a germline
mutation it will be picked up on dHPLC screening of
germline DNA, however, a somatic mutation would be
missed in both tumor and germline DNA without DNA
mixing. PCR primers and conditions were developed by
the Royal Melbourne Hospital (Australia) and are availa-
ble on request. PCR primers were used to amplify each
exon of BRCA1 (24 exons) and BRCA2 (26 exons). All
exons with abnormal dHPLC profiles were PCR amplified
and bi-directionally sequenced to identify mutations
using ABI BigDye terminator v3.1 cycle sequencing kit
(Applied Biosytems, Foster City, CA) and an ABI Prism
3100 Genetic Analyzer (Applied Biosystems, Foster City,
CA).
Multiplex Ligation-dependent Probe Amplification 
(MLPA) screening
For the identification of germline BRCA1 single and mul-
tiple exon deletions or duplications, multiplex ligation-
dependent probe amplification analysis (MLPA) kits
SALSA P002 BRCA1 and SALSA P087 BRCA1 (MRC Hol-
land, Amsterdam, NL) were used according to manufac-
turer directions. A reduction or increase in RPA values to
<0.7 or >1.3 was considered an indication of a deletion or
a duplication, respectively [49].
BRCA1 and FANCF promoter hypermethylation analysis
The BRCA1 methylation status of each tumor was assessed
using a technique similar to the MethyLight assay
described previously [50]. Briefly, 500 ng of sample DNA
was subjected to sodium bisulfite modification using the
EZ DNA Methylation-Gold Kit, as recommended by the
manufacturer (Zymo Research, Orange, CA). After
bisulfite treatment, DNA was amplified using real-time
PCR with oligonucleotide primers complementary to a
region of the MYOD1 promoter that did not contain any
CpG dinucleotides but did contain non-CpG cytosines to
ascertain the amount of converted input templates in each
sample. Hypermethylation of the BRCA1 promoter was
then examined by real-time PCR amplification of
bisulfite-modified DNA using oligonucleotide primers
specific for a fully methylated bisulfite-converted portion
of BRCA1 promoter such that only CpG islands that were
methylated at every CpG dinucleotide interrogated by the
primers and probes would be amplified and generate flu-
orescent signal. The sequences of the primers used to
amplify and detect methylated BRCA1 promoter region
were 5'-TAGAGTTTCGAGAGACGTTTGGTTT-3' (forward
primer) and 5'-CGCTTTTCCGTTACCACGA-3' (reverse
primer). The primers for MYOD1 were 5'-CCA ACTCCA
AATCCCCTC TCTAT-3' (forward primer) and 5'-TGAT-
TAATTTAGATTGGGTTTAGAGAAGGA-3' (reverse
primer). The amount of methylated DNA (PMR, percent-
age of methylated reference) [51] at the BRCA1 locus was
calculated by dividing the BRCA1: MYOD1 ratio of a sam-
ple by the BRCA1: MYOD1 ratio of CpG methylated Jur-
kat genomic DNA (New England Biolabs, Ipswich, MA)
and multiplying by 100. Reactions using CpG methylated
Jurkat genomic DNA were used to normalize for any dif-
ference in amplification efficiencies between BRCA1 and
MYOD1. The PMR serves as an index of the percentage of
bisulfite converted input copies of DNA that are fully
methylated at the primer hybridization sites. The PMR
values obtained by MethyLight were dichotomized at 4
PMR for statistical purposes as described previously [51].
Samples containing 4 PMR or higher were designated as
methylated, whereas samples containing less than 4 PMR
were designated as unmethylated. It is important to note,
however, that the PMR may be >1 if copies of MYOD1 are
deleted relative to the gene of interest, or copies of theBMC Cancer 2008, 8:17 http://www.biomedcentral.com/1471-2407/8/17
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gene of interest are gained relative to MYOD1 in any given
sample. PCR experiments were carried out in a volume of
10 μL with 384-well plates and an Applied Biosystems
7900 HT Sequence Detector (Applied Biosystems, Foster
City, CA). The fluorescence signal of the quantitative
methylation-specific PCR was generated by SYBR Green I.
Samples (10 ng bisulfite-treated DNA) were run in tripli-
cate containing 5 μL SYBR Green Master Mix (Applied
Biosystems, Foster City, CA) and 5 pmol of each forward
and reverse primer. Bisulfite-converted CpG methylated
Jurkat Genomic DNA (New England Biolabs, Ipswich,
MA) served as a positive control and was used to generate
a standard curve to quantify the amount of fully methyl-
ated promoters in each reaction. PCR amplification was
done by means of the following procedure: 95°C for 15
minutes, followed by 40 cycles at 95°C for 15 seconds,
62°C for 1 minute. A subsequent dissociation curve anal-
ysis checked the specificity of products. FANCF promoter
hypermethylation was assessed using a HpaII digest assay
and methylation-specific PCR protocol previously
reported by Taniguchi et al [52].
Real-time Q-RT-PCR
Extracted RNA was treated with DNAse I (Invitrogen,
Carlsbad, CA) prior to creating cDNA using random hex-
amer priming and MMLV reverse transcriptase (Invitro-
gen, Carlsbad, CA). Applied Biosystems Taqman primer/
probe kits (Hs00173233_m1 (BRCA1), Hs00609060_m1
(BRCA2), Hs01920652_s1 (PTEN),
Hs00907966_m1(PIK3CA)) were used to quantify mRNA
expression levels using real-time qRT-PCR [37] and an ABI
Prism 7900 HT Sequence Detection System (Applied Bio-
systems, Foster City, CA). Relative gene expression quan-
tification was calculated according to the comparative Ct
method using human 18S ribosomal RNA (Applied Bio-
systems, Foster City, CA) and commercial RNA controls
(Stratagene, La Jolla, CA). Relative quantification was
determined as follows: 2-(ΔCt sample-ΔCt calibrator). Ratios
(tumor relative gene expression:average of all tumors) less
than 0.7 or greater that 1.3 for were scored as decreased or
increased mRNA expression, respectively.
Immunohistochemistry
The BRCA1 antibody Ab-1 (Oncogene, 1:50 dilution) was
used and antigen retrieval was performed in 1× EDTA
buffer (pH 8.0) by microwaving for 2 minutes, and then
boiling in a waterbath for 30 minutes. Endogenous perox-
ide activity was blocked with 3% hydrogen peroxide and
then sections were incubated with 2.5% normal horse
blocking serum. Following incubation with the primary
antibody, the Vector Laboratories (Burlingame, CA)
ImmPRESS kit was used according to the manufacturer's
recommendations to visualize antibody complexes.
Nuclear staining was assessed by CBG, who was blinded
to all other BRCA analysis. Tumors were considered
BRCA1 positive if greater than 1% of tumor nuclei showed
staining. IHC was also performed with the following
panel of previously validated antibodies using a Ventana
(Tucson, AZ) automated immunostainer: p21 (Neomark-
ers, Fremont, CA, clone DCS-60.2, 1:100 dilution), p53
(Dako, Carpinteria, CA, clone DO-7, 1:400 dilution), and
WT-1 (Dako, Carpinteria, CA, clone 6F-H2, 1:50 dilu-
tion). BRCA1 IHC was done on whole sections, while
other IHC markers were assessed using sections from a tis-
sue microarray constructed with two 0.6 mm cores per
case.
Molecular Inversion Probe (MIP) Copy Number
The MIP copy number assay was done as described previ-
ously [53] with some modifications. Specifically, the cur-
rent protocol is a modification of the Targeted
Genotyping protocol commercialized by Affymetrix [54].
Test DNA samples were diluted to16 ng/μl. Molecular
inversion probes were annealed to DNA by mixing 4.7 μl
of DNA (75 ng total), 0.75 μl of Buffer A, 1.1 μl of the 53
K molecular inversion probe pool (200 amol/μl/probe)
and 0.045 μl of Enzyme A in a 384-well plate on ice. The
reaction was incubated for 4 min at 20°C, 5 min at 95°C,
then overnight at 58°C. Following annealing, 13 μl of
Buffer A and 1.25 μl of Gap Fill Enzyme mix were added
to each reaction and 9 μl of reaction volume was trans-
ferred to each of two wells in a 96-well plate. Molecular
inversion probes were circularized with 4 μl of dNTP mix
at 58°C for 10 min. Linear probes and genomic DNA were
eliminated by addition of 4 μl of Exo Mix and incubation
at 37°C for 15 min, followed by universal primer ampli-
fication for 18 cycles (20 sec at 95°C, 40 sec at 64°C, and
10 sec at 72°C). For labelling reactions, the product was
further amplified for 10 cycles using labelled primers,
then subjected to cleavage by HY Digest Mix at 37°C for 2
hours. The cleaved MIP products were mixed with Hybrid-
ization Cocktail, denatured, and hybridized to 70 K Uni-
versal Taq arrays at 39°C for 16 h (two arrays per sample).
The overnight hybridized arrays were washed on a Gene-
Chip® Fluidics Station FS450 and stained by SAPE at 5 ng/
ml (Invitrogen).
Copy number estimation was obtained from the hybridi-
zation signals as previously described [55], with the fol-
lowing modifications: the color-separation step was
omitted as the single color readout on two arrays pre-
vented the spectral overlap that occurs with multi-color
readouts, and Langmuir correction was performed instead
of linear calibration of allele signals [56]. Copy numbers
over 3.0 were considered amplification events and copy
numbers below 1.5 were considered deletion events.
Data analysis
Epigenetic BRCA1 loss was defined as having promoter
hypermethylation accompanied by either low relativeBMC Cancer 2008, 8:17 http://www.biomedcentral.com/1471-2407/8/17
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BRCA1 mRNA expression, negative BRCA1 IHC, or both
low BRCA1 mRNA and negative BRCA1 IHC. Tumors
without promoter hypermethylation and with positive
BRCA1 IHC were not considered to have BRCA1 loss.
Tumors with negative BRCA1 IHC without promoter
hypermethylation were considered equivocal for BRCA1
loss. A chi-squared test or Fisher exact test was used to ana-
lyze categorical variables (MIP copy number, IHC) and a
student's t-test was used to analyze continuous variables
(RNA expression).
Results
Representative results of analysis for BRCA1 mutations,
BRCA1 loss of heterozygosity, and BRCA1 promoter
hypermethylation are shown in Figure 1.
BRCA1 findings for all tumors are presented as Figure 2.
Based on these results, ovarian cancers were divided into
six groups: (1) BRCA1 mutations, (2) BRCA1 epigenetic
loss, (3) equivocal for BRCA1 loss, (4) high grade serous/
undifferentiated cancers without BRCA1 loss, (5) BRCA2
mutations, and (6) clear cell, endometrioid, and low
grade serous cancers.
Nine of the samples (18%) carried BRCA1 mutations
(eight germline, one somatic) and three samples (6%)
had BRCA2 mutations (two germline, one somatic). No
intragenic deletions in BRCA1 were detected by MLPA
analysis. Nine samples (18%) were found to have loss of
BRCA1 due to epigenetic events; these samples all had
hypermethylation of the BRCA1 promoter accompanied
by decreased BRCA1 mRNA levels (relative qRT-PCR
expression <0.7) and/or lack (less than 1% of tumour
nuclei) of BRCA1 immunohistochemical staining. Five
samples (10%), which did not carry BRCA1 mutations,
were all unmethylated at the BRCA1 promoter; these were
classified as "equivocal for BRCA1 loss" because they ful-
filled two of the following criteria: loss of heterozygosity
(LOH) at the BRCA1 locus, decreased BRCA1 mRNA lev-
els, or lack of BRCA1 immunohistochemical staining. All
samples (n = 26) with BRCA1 or BRCA2 mutations, epige-
netic loss of BRCA1, or classified as equivocal for BRCA1
loss were of high grade serous/undifferentiated type.
Twelve tumors (24%) of high grade serous/undifferenti-
ated type did not have BRCA1 mutations or epigenetic
loss, or BRCA2 mutations. Thus, considering only the 38
high grade serous/undifferentiated tumours in our study,
18 (18/38, 47%) had loss of BRCA1 either through
genetic or epigenetic events, three (3/38, 8%) carried
germline or somatic BRCA2 mutations, 12 (12/38, 32%)
had preservation of BRCA1 expression and no mutations
in BRCA1 or BRCA2, and the remaining five tumors (5/
38, 13%) were equivocal for BRCA1 loss and did not have
BRCA2 mutations. FANCF promoter hypermethylation
was not observed in any of these cases.
The remaining 11 tumour samples (22%) (i.e. those cases
other that the high grade serous/undifferentiated carcino-
mas) were either clear cell (4), endometrioid (5), or low
grade serous type (2). These samples were all negative for
BRCA1 or BRCA2 mutations, negative for BRCA1 pro-
moter hypermethylation, and positive for BRCA1 expres-
sion as determined by immunohistochemistry.
We further analyzed the 35 high grade serous/undifferen-
tiated tumour samples that did not contain BRCA2 muta-
tions using a combination of MIP copy number, qRT-
PCR, and immunohistochemistry in order to determine
whether these different groups could be classified accord-
ing to specific molecular features other than BRCA1 or
BRCA2 abnormalities (Figure 3). The number of tumors
with BRCA2 mutations (n = 3) was considered too small
for meaningful further analysis of this subset and was
therefore excluded. Thirty-one of these tumours were pos-
itive for WT1 expression by immunohistochemistry, a
marker of serous cell type in EOC, thus confirming our
histopathological subclassification [57]; all clear cell and
endometrioid cancers in this study were negative for WT1
expression (data not shown). Currently, the group of high
grade serous/undifferentiated carcinoma is indivisible
based on morphology or routinely used diagnostic molec-
ular markers. We specifically focused on the PI3K/AKT
and p53 pathways which are known to be important in
EOC. We found that those tumours with BRCA1 loss
through genetic events differed according to several
parameters from tumours with loss of BRCA1 due to epi-
genetic events. Most striking were differences in PIK3CA
copy number as determined by the MIP copy number
assay. While none of the BRCA1 mutation positive cases
demonstrated an increased PIK3CA copy number almost
all (7/8) of the samples with epigenetic loss of BRCA1 had
increased copy number at the PIK3CA locus. The PIK3CA
copy number increases were low level (mean amplifica-
tion ratio 2.7, range 1.7–4.9), and in all but one case
amplification of PIK3CA was associated with amplifica-
tion of the entire chromosomal arm. PIK3CA mRNA lev-
els were assessed using qRT-PCR and relative mRNA levels
were found to correlate with copy number ratios (p =
0.02). Specificity of MIP copy number data was verified by
assessing c-myc amplification; while PIK3CA copy
number appeared to be selectively increased in specific
subgroups, amplification at the c-myc locus was observed
at similar frequencies in all subgroups. Interestingly,
decreased PTEN mRNA levels observed in cancers with
BRCA1 mutations and increased PI3KCA copy number in
cancers with epigenetic loss of BRCA1 were almost mutu-
ally exclusive (Figure 4). These events represent two sepa-
rate mechanisms of activation of the canonical PI3K/AKT
pathway.BMC Cancer 2008, 8:17 http://www.biomedcentral.com/1471-2407/8/17
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Assessment of BRCA1 loss (A) Mutation screening showing the abnormal denaturing high performance liquid chromatography  profile corresponding to the 1351delAT mutation in tumor 223 Figure 1
Assessment of BRCA1 loss (A) Mutation screening showing the abnormal denaturing high performance liquid chromatography profile corresponding to 
the 1351delAT mutation in tumor 223. The single blue line represents the electropherogram from a normal control, while the purple line represents the 
abnormal profile formed by the mutated exon 11c in tumor 223. (B) Direct DNA sequencing demonstrating the 185delAG mutation in tumor 283. Only 
the mutant allele is seen in the tumor because LOH is present. (C-E) Loss of heterozygosity (LOH) analysis using BRCA1-associated microsatellite mark-
ers visualized on an ABI Prism 3100 Genetic Analyzer, where LOH is defined as >50% decrease in area under the curve when germline DNA (upper trac-
ing) and tumor DNA (lower tracing) are compared. (C) The lack of LOH in tumor 240 demonstrated using microsatellite marker D17S1185, (D) LOH in 
tumor 283 demonstrated using microsatellite marker D17S855. (E) Microsatellite instability demonstrated in tumor 156 using microsatellite marker 
D17S1185. (F, G, H, and I) Methylation analysis of BRCA1 gene using fluorescence-based, quantitative, real-time PCR (TaqMan) using SYBR Green 1 as 
detection method. Two sets of primers, designed specifically for bisulfite converted DNA, were used: a methylated set for the BRCA1 gene and a refer-
ence set (MYOD1) to control for input DNA. Specificity of the reactions for methylated DNA were confirmed separately using human genomic DNA 
(unmethyated; F) and CpG methylated Jurkat genomic DNA (methylated; G), respectively. H and I show representative examples of results from assess-
ment of BRCA1 loss through promoter hypermethyation. Tumor 178 shows only unmethylated BRCA1 promoter, while tumor 345 shows evidence of 
BRCA1 promoter hypermethylation.
Human genomic DNA
MYOD1
BRCA1
MYOD1
BRCA1
CpG methylated Jurkat genomic DNA
(F)
(I) (H)
(G)
MYOD1
BRCA1
345 178
MYOD1
BRCA1BMC Cancer 2008, 8:17 http://www.biomedcentral.com/1471-2407/8/17
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We further compared those tumors with either genetic or
epigenetic loss of BRCA1 with high grade serous cancers
without evidence of BRCA1 loss (Table 1). Representative
immunohistochemical images for BRCA1, p53, and p21
from all three of these groups are shown in Figure 5. MIP
copy number analysis of the nine tumours that had
BRCA1 mutations showed that there was no loss or gain
at the region of chromosome 3 that contains the gene for
PIK3CA and only four (44%) samples stained positively
for p53. By contrast, of the samples that had loss of
BRCA1 due to epigenetic events, seven of eight samples
(88%) had an increased PIK3CA copy number, and eight
of nine samples (89%) stained positively for p53. In addi-
tion, high grade serous cancers without BRCA1 loss had
low frequencies of positive p53 staining (4/12, 33%) and
increased PIK3CA copy number (3/12, 25%), similar to
cancers with BRCA1 mutations but distinct from cancers
with epigenetic loss of BRCA1. In two cases (#366 and
#217) we were unable to obtain MIP copy number data. It
was noted that positive p53 staining was most often
accompanied by negative p21 staining. The expression of
p21 is increased in response to p53. High level overexpres-
sion of p53 correlates with p53 mutations and loss of
function and would be anticipated to be associated with
decreased p21 expression, as we observed. This p53+/p21-
immunophenotype was significantly more common in
tumors with BRCA1 epigenetic loss than in tumors with-
out BRCA1 loss (Table 1).
Discussion
The sub-classification of ovarian carcinomas, which is
based on histopathological subtype and grade, is unable
to adequately predict prognosis or response to treatment.
Administration of adjuvant platinum/taxane chemother-
Summary of analysis of high grade (HG) serous/undifferenti- ated ovarian tumors: MIP copy number results are shown for  c-myc and PIK3CA loci Figure 3
Summary of analysis of high grade (HG) serous/undifferentiated ovarian 
tumors: MIP copy number results are shown for c-myc and PIK3CA loci. 
MIP copy number values over 3.0 are highlighted and correspond to ampli-
fication. Relative mRNA levels for PIK3CA and PTEN were assessed using 
qRT-PCR; levels over 1.3 (highlighted in green) are considered elevated 
and levels below 0.7 (highlighted in aqua) indicate decreased transcript lev-
els. Associated immunohistochemical markers p21, p53, and WT-1 refer 
to immunohistochemical staining results. Scoring of immunostaining was 
done as follows: p21: 0 = <5% nuclei positive and 1 = >5% of nuclei posi-
tive. p53: 0 = <50% nuclei positive and 1 = >50% of nuclei positive. WT1: 
0 = <5% nuclei positive, 1 = 5–50% nuclei positive, and 2 = >50% nuclei 
positive. N/A indicates that the data is not available for technical reasons.
qRT-PCR
# Pathology C-MYC PIK3CA PIK3CA PTEN p21 p53 WT1 Classification
186 Ser/Undiff-HG 2.4 2.7 1.68 0.58 0 0 2
223 Serous - HG 5.8 2.5 0.48 0.32 0 1 2
329 Serous - HG 3.4 2.0 0.1 0.11 0 1 2 BRCA1 loss
293 Serous - HG 2.6 2.4 1.05 0.94 1 0 2 through
283 Serous - HG 3.3 2.0 0.62 0.55 0 1 2 germline or
239 Serous - HG 3.0 2.3 0.33 0.45 0 0 0 somatic
336 Ser/Undiff-HG 9.6 1.7 0.12 0.06 1 0 0 mutation
327 Serous - HG 2.0 2.4 0.07 0.1 0 1 2
379 Serous - HG 3.6 2.0 0.68 0.33 1 0 2
217 Serous - HG NA NA 1.18 1.14 0 1 2
330 Serous - HG 2.9 3.2 0.42 0.52 0 1 2
332 Serous - HG 5.1 4.9 2.08 0.99 0 1 2 High
388 Serous - HG 3.2 2.9 1.12 0.67 0 1 2 grade
363 Serous - HG 5.0 3.6 3.31 1.37 0 0 2 carcinoma
161 Ser/Undiff-HG 2.5 3.0 1.02 0.39 0 1 2 with
344 Serous - HG 3.0 3.3 1.6 0.89 0 1 2 epigenetic
345 Serous - HG 5.8 3.9 2.02 0.39 0 1 2 BRCA1 loss
384 Serous - HG 3.8 3.2 2.53 2.69 0 1 2
178 Serous - HG 5.7 2.8 2.64 0.75 0 1 2
229 Serous - HG 4.2 3.1 0.29 0.32 0 1 2
309 Serous - HG 1.9 2.2 1.18 2.2 N.A. 0 2 Equivocal
394 Serous - HG 2.4 2.2 1.05 0.72 0 0 2 BRCA1 loss
201 Ser/Undiff-HG 2.7 2.9 0.75 2.65 0 1 2
195 Serous - HG 3.9 2.1 1.09 2.71 0 1 2
236 Serous - HG 3.3 2.7 1.22 0.94 0 0 2
280 Ser/Undiff-HG 7.7 3.1 2.18 0.66 1 1 2
172 Serous - HG 2.1 1.8 0.86 0.74 1 0 0 High grade
254 Serous - HG 2.9 2.0 0.38 0.58 0 0 2 carcinoma
319 Serous - HG 3.2 1.9 0.4 0.75 1 0 2 without
372 Serous - HG 4.0 3.6 2.89 1.36 1 0 1 BRCA1 loss
208 Undiff - HG 4.9 3.7 1.03 1.06 0 0 2
273 Undiff - HG 3.9 1.9 0.33 0.39 0 1 1
240 Undiff - HG 2.8 2.2 0.36 0.47 1 0 0
297 Serous - HG 2.0 2.2 2.06 3.14 0 0 2
366 Serous - HG NA NA 0.83 0.66 0 1 2
MIP COPY NUMBER IHC
Summary of BRCA1 abnormalities and associated features:  Pathology refers to the tumor histopathology Figure 2
Summary of BRCA1 abnormalities and associated features: Pathology 
refers to the tumor histopathology. Serous or Ser = serous carcinoma; 
Undiff = undifferentiated carcinoma; HG = high-grade; LG = low-grade; 
Clear cell = clear cell carcinoma; Endo = endometrioid carcinoma; G1 = 
grade 1; G2 = grade 2; G3 = grade 3. BRCA1 Status: Mut = mutation; G = 
germline; S = somatic; N = no mutations. LOH = loss of heterozygosity 
where LOH indicates that loss of heterozygosity is present, NO indicates 
that loss of heterozygosity is not present, and MSI indicates that microsat-
ellite instability is present in the tumor. Meth refers to BRCA1 promoter 
hypermethylation. Tumors containing ≥ 4% fully methylated molecules are 
designated as methylated (M) and are highlighted in orange, whereas 
tumors containing < 4% are designated as unmethylated (U). RNA refers 
to relative RNA expression compared to the average RNA expression in 
all samples, where the average RNA expression = 1.0. Tumors with rela-
tive RNA expression <0.7 are highlighted in aqua as showing BRCA1/
BRCA2 loss. IHC refers to BRCA1 immunohistochemistry; (+) indicates 
tumors with > 1% of nuclei stained positive for BRCA1, (-) indicates 
tumors with <1% of nuclei positive. N/A indicates that the data is not avail-
able for technical reasons.
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apy is the standard treatment for ovarian carcinoma fol-
lowing debulking surgery [58]. Approximately 70% of
advanced-stage ovarian carcinomas, however, will recur
with development, ultimately of platinum-resistant dis-
ease [59]. A comparison of clinical outcomes between
ovarian cancer patients with BRCA1 promoter hypermeth-
ylation to patients with BRCA1 mutations and wild-type
BRCA1 genes demonstrated that patients with BRCA1
promoter hypermethylation had significantly shorter sur-
vival times compared to the other two groups [60]. Ovar-
ian carcinomas in patients with BRCA1, in contrast are
associated with a favourable prognosis [23,61]. This data
suggests that different abnormalities in BRCA1 could be
associated with different clinical outcomes and possibly
distinct alterations in other underlying molecular abnor-
malities. For example, the colon cancers from patients
with inherited mutations in DNA mismatch repair genes
differ from sporadic cancers with microsatellite instability
due to hypermethylation of the MLH1 promoters [62],
with respect to age of onset of disease, pathology, and
molecular alterations [63].
We evaluated 49 ovarian carcinomas and categorized
them according to pathology and BRCA1 and BRCA2 sta-
tus. We further evaluated 35 high grade serous/undiffer-
entiated tumours that we divided into four groups based
on BRCA1 mutation status, expression, and promoter
hypermethylation. We observed increased positive p53
immunohistochemical staining, which correlated with
negative p21 immunostaining, in cancers with epigenetic
BRCA1 loss, compared to cancers with BRCA1 mutations
and high grade serous/undifferentiated cancers without
BRCA1 loss. p53 is a tumor suppressor that is involved in
the progression of many cancers and is the most com-
monly mutated gene in ovarian carcinomas [37]. Typi-
cally, mutations in p53 result in accumulation of p53 in
the nucleus and the majority of cases with abundant p53
detectable by immunohistochemistry are p53 mutant
[64,65]. The p53 protein is an important mediator of
apoptosis resulting from DNA damage, stress, or chemo-
therapy [66]. p21 is a downstream effector of the cell cycle
arrest function of p53 and is upregulated at the transcrip-
tional level by wildtype but not mutated p53 [67]. At
present, p53 mutation status or expression is not used to
guide clinical decisions [68]. We have observed that p53
overexpression correlates, as expected, with loss of p21
expression. Furthermore the phenotype of p53 overex-
pression with loss of p21 is significantly more common is
high grade serous/undifferentiated tumors with epige-
netic loss of BRCA1 compared to high grade serous/undif-
ferentiated tumors without loss of BRCA1.
In addition, we found that ovarian carcinomas with loss
of BRCA1 through genetic events and those with BRCA1
loss through epigenetic events both have activation of the
PI3K/AKT pathway, though the mechanism of activation
is different. PI3K phosphorylates phosphatidylinositol
lipids in response to activation by receptor tyrosine
kinases [69]. Its activity has been linked to proliferation,
differentiation, cell adhesion, apoptosis, tumorigenesis,
and angiogenesis [70]. PTEN is a phosphatase whose
activity counters PI3K. The serine/threonine kinase AKT is
a downstream target of PI3K [71] and the activity of one
of its isoforms, AKT1, is elevated in ovarian carcinomas
[72]. Both decreased PTEN levels and amplification of
PIK3CA lead to increased phosphorylation of AKT and it
has been previously shown that ovarian cancers often
have alterations in PI3K and PTEN [73-75]. This is the first
study, however, to report that decreased PTEN expression
levels are associated with ovarian carcinomas carrying
BRCA1 mutations while increased PI3KCA copy number
is associated with ovarian carcinomas with epigenetic loss
of BRCA1. It has been previously demonstrated in breast
cancer and glioblastoma that PIK3CA mutations and
PTEN loss are virtually mutually exclusive, suggesting that
abrogation of just one of these proteins is sufficient for
tumorigenesis [76,77]. We observe a similar result in our
ovarian serous cancer samples; it is likely that deregula-
tion of this pathway, while critical for tumorigenesis, can
be accomplished through alteration of a single key mole-
cule at which point selective pressure is relieved for alter-
ing other proteins involved in this signalling pathway.
Our findings in serous ovarian carcinoma, and the previ-
ous results from studies of breast cancer and glioblast-
oma, are in contrast to ovarian carcinoma of
Correlation between decreased PTEN mRNA levels and  amplification at the PIK3CA locus Figure 4
Correlation between decreased PTEN mRNA levels and amplification at 
the PIK3CA locus: Relative PTEN mRNA levels as determined by qRT-
PCR are plotted along the X-axis and PIK3CA MIP copy number results 
are plotted along the Y-axis for high grade serous ovarian tumors with 
BRCA1 mutations (open circles) and high grade serous ovarian tumors 
with epigenetic loss of BRCA1 (filled triangles). MIP copy number values 
over 3.0 indicate amplification.BMC Cancer 2008, 8:17 http://www.biomedcentral.com/1471-2407/8/17
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endometrioid type [78], and endometrial cancer [79,80],
where PTEN mutations and PIK3CA mutations frequently
co-exist. This is yet another example of molecular events
during the genesis of ovarian cancer that show tumor cell
type specificity, and reinforces the need to consider cell
type differences in studies of ovarian cancer pathogenesis.
We would expect that cancers with activation of the PI3K/
AKT pathway may not respond well to common chemo-
therapy, as overexpression of activated AKT decreases
apoptosis induced by paclitaxel in ovarian cancer cells
[81] and introduction of the catalytic subunit of PI3K into
ovarian cancer cells causes resistance to paclitaxel [82]. In
addition, the PI3K inhibitor, LY294002, has been shown
to decrease growth of ovarian carcinoma and ascites for-
mation in mouse xenograft models of ovarian carcinoma
[83]. As therapies continue to be developed that target the
PI3K/AKT pathway, it will be essential to understand the
molecular alterations that are affecting this pathway in
different types of ovarian carcinomas.
The need for meaningful sub-classification of ovarian car-
cinoma is critical for improving the treatment and prog-
nosis of patients. Though sub-classification may be done
based on BRCA1 genetic testing, this cannot be done in a
timely fashion such that it could be used to guide therapy
Table 1: Comparison of PIK3 CA amplification or p53/p21 protein expression in High Grade Serous Ovarian Tumours
Group PIK3CA amplification (MIP copy number) p53/p21 IHC
+/- +/+, -/- -/+
BRCA1 loss through mutation 0/9*+ 4/9 2/9 3/9
BRCA1 epigenetic loss 7/8*+ 8/9** 1/9 0/9
No BRCA1 loss 3/11+ 3/12** 5/12 4/12
* p = 0.02 for pairwise comparison based on Bonferroni-Holmes corrected Fisher exact test
** p = 0.03 for pairwise comparison based on Bonferroni-Holmes corrected Fisher exact test
+ p = 0.001 for threeway comparison based on Bonferroni-Holmes corrected Fisher exact test
Immunohistochemistry results: Representative immunohistochemistry results for high grade serous ovarian tumors with  BRCA1 mutations (tumor #327, top row), with epigenetic loss of BRCA1 (tumor #332, middle row), and without loss of  BRCA1 (tumor #372, bottom row) Figure 5
Immunohistochemistry results: Representative immunohistochemistry results for high grade serous ovarian tumors with BRCA1 mutations (tumor #327, 
top row), with epigenetic loss of BRCA1 (tumor #332, middle row), and without loss of BRCA1 (tumor #372, bottom row). Immunohistochemical stain-
ing is shown for BRCA1 (left column), p53 (middle column) and p21 (right column).BMC Cancer 2008, 8:17 http://www.biomedcentral.com/1471-2407/8/17
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of patients newly diagnosed with ovarian cancer. This is
extremely important as patients must embark on therapy
shortly after diagnosis. In addition, as new therapeutics
are developed, rapid identification of appropriate patients
will be necessary for clinical trials. Our results demon-
strate that it may be possible to categorize patients based
on rapid molecular tests to identify patients who are likely
to harbour BRCA1 mutations. Negative BRCA1 immuno-
histochemical staining, decreased BRCA1 mRNA, lack of
PI3K amplification, and absence of BRCA1 promoter
hypermethylation is an example of a molecular profile
that could be used to identify these patients. This would
also allow more cost effective and efficient mutation
screening in patients presenting with ovarian carcinoma.
Conclusion
This is the first study to comprehensively examine data
from detailed analysis of BRCA1 and BRCA2 abnormali-
ties in ovarian cancer. Results presented here demonstrate
that high grade serous/undifferentiated carcinomas can be
subclassified based on the underlying BRCA abnormali-
ties. Such clinically relevant subclassification is critical for
developing specific treatements for ovarian cancer
patients which will lead to improved prognosis and man-
agement of disease.
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